HER-2/neu-positive breast carcinoma: Molecular concomitants by proteomic analysis and their therapeutic implications

Annals of Clinical and Laboratory Science

Volumn 32, Issue 1, 2002, Pages 12-21

  Brown, Robert E ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Breast carcinoma; Carcinogenesis; HER 2 neu; Molecular pathways

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 11; INTERLEUKIN 6; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROSTAGLANDIN SYNTHASE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR DYNAMICS; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CARCINOMA; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEOME; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0036172141     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Overexpression of Erb B2 in cancer and Erb B2- targeting strategies
3. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
4. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
5. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
6. Identification and characterization of c-erbB-2-proteins in serum, breast tumor tissue, and SK-BR-3 cell line
7. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
8. Human transforming growth factors induce tyrosine phosphorylation of EGF receptors
9. Just another signalling pathway
10. Molecular pathology of cyclooxygenase-2 in neoplasia
11. Histogenesis of Reed-Sternberg and dendritic interdigitating cells in nodular sclerosing Hodgkin's disease. Immunohistochemical evidence for monocytoid precursors
12. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA
13. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
14. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast cancer patients
15. Mitogenic and anti-apoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells
16. RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells
17. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides
18. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells
19. Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the Erb B-2 pathway in human breast adenocarcinoma cells
20. Branched chain organic acidurias
21. Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein: Farnesyltransferase to different extents
22. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation
23. Immunohistochemical analysis of DNA mismatch-repair enzyme hMSH-2 and Ki-67 in breast carcinomas
24. Latent forms of TGF-β: Structure and biology
25. Effects of TGFβ on normal and malignant mammary epithelium
26. Roles for transforming growth factors-β in the genesis, prevention, and treatment of breast cancer
27. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells
28. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells
29. Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: Evidence for negative autocrine regulation by transforming growth factor beta
30. Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-beta and tumor cell factors
31. Interleukin-11: A new cytokine critical for osteoclast development
32. Regulation of natural killer cell activity by transforming growth factor-β and prostaglandin E2
33. Activated alpha-2-macroglobulin reverses the immunosuppresive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2
34. Transforming growth factor beta, secreted by immunogenic ex vivo human carcinoma cells, counteracts the activation and inhibits the function of autologous cytotoxic lymphocytes. Pretreatment with interferon gamma and tumor necrosis factor alpha reduces the production of active TGF beta
35. Immunoregulatory role of transforming growth factor β in development of killer cells: Comparison of active and latent TGF-β1
36. Recent developments in breast cancer therapy
37. Inhibition of ras oncogene: A novel approach to antineoplastic therapy
38. Ras-mediated suppression of TGF beta RII expression in intestinal epithelial cells involves Raf-independent signaling
39. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras
40. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
41. Inhibitors of farnesyl transferase in oncology: From basic research to pharmaceutical research
42. Bisphosphonate risedronate reduces metastatic human cancer burden in bone in nude mice
43. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice
44. Bisphosphonates induce apoptosis in human breast cancer cell lines
45. The role of bisphosphonates in metastatic breast cancer
46. Therapeutic valve of aredia in treatment of breast carcinoma
47. Bisphosphonate therapy for bone metastases from breast cancer: Clinical results and a new therapeutic approach
48. Lovastatin induces apoptosis in malignant mesothelioma cells
49. Requirement for mevalonate in the control of proliferation of human breast cancer cells
50. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses
51. Antitumor effect and potentiation ofcytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
52. ZD 1839 "Iressa."
53. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER-2/neu-overexpressing metastatic breast cancer
54. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
55. N-(4-hydroxyphenyl) retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells
56. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl) retinamide
57. Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells
58. Retinoids control the expression of c-erbB receptors in breast cancer cells
59. Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells
60. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer
61. Retinoids, breast cancer and NK cells
62. Tyrosine kinase signaling pathways control the expression ofretinoic acid receptor-alpha in SK-BR-3 breast cancer cells
63. Molecular portraits of human breast tumours
64. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers